Birmingham Clinical Trials Unit
Birmingham, West Midlands, B15 2TT, United Kingdom
NCT Number: NCT02179294
Childbirth can be an extremely painful and the provision of pain relief during labour is a vital component of a positive maternal experience. The majority of women who deliver in modern obstetric units choose a pharmacological method of pain relief, including Entonox, the injection of opioids or epidural placement. The commonest opioid used in labour is pethidine administered by intramuscular (im) injection. The effectiveness of pain relief provided by pethidine has long been challenged. Its shortcomings are more serious when set against known side effects including maternal sedation, nausea and potential transfer across the placenta to the foetus. More than a third of women who receive pethidine subsequently require an epidural due to inadequate pain relief. Epidurals provide highly effective pain relief, but increase the risk of a forceps or suction delivery resulting in prolonged hospital stay. Therefore, there is a clear need for a safe, effective, easy to administer analgesic alternative.
Looking for future studies?
Notify Me16 year and older
Female
Interventional
Phase 4
Birmingham, West Midlands, B15 2TT, United Kingdom
Patient Controlled Analgesia (PCA) comprises drug administration into an intravenous drip with a small dose given each time a woman presses a button, giving her control over her own pain relief. The pump is programmed to ensure that the maximum dose allowable is within the safe range. This form of delivery of pain relief matches the drug dose to pain sensation within the relevant time frame, which is not possible using a single dose intramuscular injection. Whilst PCA is in widespread use for acute pain relief it has only a limited role in obstetrics. The most common drug given by PCA is morphine, however, since it has a long duration of action and crosses the placenta, the potential for accumulation in the foetus and consequent neonatal sedation at delivery restricts its utility (within obstetrics) to contexts where neonatal status is not relevant, such as intra-uterine foetal death or foetal abnormality incompatible with survival.
Remifentanil is a novel synthetic opioid with a very rapid onset (blood-brain equilibration 1.2-1.4 minutes) and short duration of action (context specific half-life 3 minutes), giving it an analgesic profile which potentially makes it ideal for providing pain relief over 1-2 uterine contractions after a single intravenous dose. It is subject to rapid redistribution and metabolism by non-specific blood and tissue esterases negating the potential for accumulation in mother or foetus. Administration of remifentanil by PCA has been investigated in several small studies in comparison to pethidine and shown to provide useful, although not complete, pain relief in labour.10-12 Thus far, there is no evidence of detrimental neonatal effects in comparison to other opioids.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Women who are admitted to labour ward who fulfil all the following criteria will be eligible to be randomised:
Exclusion criteria
100mg by intramuscular injection, up to 4 hourly in frequency (up to a maximum of 4 doses). The maximum dose being 400mg in 24 hours.
Other names: Meperidine
Dedicated intravenous cannula for remifentanil administration PCA protocol
In the event of excess sedation being recorded by regular observation of respiratory function, the regimen will be altered by reduction of the remifentanil bolus dose to 30 μg with a lock-out interval of 2 minutes.
Other names: Ultiva
Time frame: At labour
The proportion of women who receive epidural analgesia for pain relief in labour, in each group, after randomization.
Time frame: Post natally - Average of 2-3days after delivery
Time frame: Post Natally - Average of 2-3days after delivery
The incidence of maternal side effects including
Time frame: Post Natally - Average of 2-3days after delivery
Delivery mode (Spontaneous, Instrumental Vaginal, Caesarean Section)
Time frame: Post Natally - Average of 2-3days after delivery
Incidence of foetal distress requiring delivery
Time frame: Post Natally - Average of 2-3days after delivery
Neonatal status at delivery:
Time frame: Post Natally - 1 hour after delivery
Rate of initiation of breast feeding within the first hour of birth
Time frame: Post Natally - Average of 2-3days after delivery
Maternal satisfaction with childbirth experience determined by postpartum questionnaire prior to discharge from the delivery ward
Time frame: Up to 6 weeks post-partum
Explore and compare women's birth experiences up to six weeks postpartum via qualitative telephone interview (Post-Natal sub-study)
Time frame: Up to 6 weeks post-partum
Explore and compare women's perceptions of pain relief up to six weeks postpartum via qualitative telephone interview (Post-Natal sub-study)
Time frame: Up to 6 weeks post-partum
Explore and compare infant feeding behaviours up to six weeks postpartum via qualitative telephone interview (Post-Natal sub-study)
University of Birmingham
Other
Acronym: RESPITE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.